31 results about "Antigen variation" patented technology

The invention provides antigen polypeptide, a polypeptide composition and a vaccine for preparing a porcine circovirus synthetic peptide vaccine. The antigen polypeptide is polypeptide shown in the sequence 1, sequence 2, sequence 3 or sequence 4. The synthetic peptide vaccine comprises polypeptide or a polypeptide composition. The provided porcine circovirus synthetic peptide vaccine is excellent in immune effect and doesn't cause problems of fever and redness existing in conventional vaccine. The vaccine can effectively overcome the problems including antigenic variation of porcine circovirus and absence of biological safety, is easy for massive synthesis, and has bright application prospects. The invention further provides a preparation method of polypeptide and a polypeptide vaccine and a pharmaceutical application thereof.

The invention relates to the field of animal virology, and provides separation, identification and application of an avian H9N2 subtype avian influenza virus strain. The H9N2 subtype avian influenza virus strain is preserved in China General Microbiological Culture Collection Center on July 02, 2019 with the preservation number of CGMCC No. 18172. The antigen variation condition of the separated strain is explained from the molecular level; the virus strain is inactivated with formaldehyde, and then is processed together with a 605 adjuvant to prepare an inactivated vaccine, 21-day-old SPF chickens are immunized, the immune effect is evaluated through a serological method and an immune challenge method, it is proved that the strain is good in protection effect, and the strain can be used as an avian influenza H9N2 subtype vaccine candidate strain. The invention provides an idea for bird flu prevention and control, provides technical teaching for bird flu candidate strain screening, andhas great public health significance.

The present invention relates to a novel MDCK-derived cell line capable of being suspension-cultured in a protein-free medium and a method for proliferating a virus using the MDCK-derived cell line to produce a vaccine. The novel MDCK-derived cell line exhibits high and uniform productivity for various viruses, while causing less viral antigenic variations with low tumorigenicity, and thus can be useful in producing viruses used for vaccines.

The invention provides an adaption method of influenza virus vaccine strains on Vero cells. The influenza virus vaccine strains are rapidly adapted on the Vero cells; and various effective virus adaption methods are established, so that influenza virus seeds can be adapted on the Vero cells, and virus progenies used as vaccines are produced under the condition of minimizing virus surface antigen variation caused by virus adaptation selection. The hemagglutination titer of the virus seeds prepared by vaccine strains adapted by the method is more than or equal to 160, and meets the requirementsof three parts of the Chinese pharmacopoeia, 2010 edition.

The invention provides an Asia I synthetic peptide vaccine of a foot and mouth disease, in particular to a polypeptide or a polypeptide polymer thereof for the Asia I synthetic peptide vaccine of the foot and mouth disease, the vaccine containing the polypeptide or the polypeptide polymer thereof, and a preparation method of both, wherein, the amino acid sequence of the polypeptide is shown as SEQ ID NO:1. In the invention, variation situation of main antigen sites of the foot and mouth disease is researched by determining a sequence of an epidemic strain of the foot and mouth disease, and meanwhile analysis prediction of the antigen sites of the foot and mouth disease is performed followed by chemical synthesis on possible peptide segments of the antigen sites combined with a computer auxiliary method; and candidate polypeptide antigens are screened through a large quantity of animal experiments to finally obtain the polypeptide antigens with high immune reaction level which can protect well an animal from being attacked by the epidemic strain of the foot and mouth disease. The vaccine prepared from the polypeptide antigens has the advantages of no biological safety problem, easylarge-scale synthesis, good application prospect and good ability of effectively dealing with antigen variation of foot and mouth disease virus.

The invention relates to the field of animal virology, and provides the isolation, identification and application of an avian H9N2 subtype avian influenza virus strain. The H9N2 subtype avian influenza strain was deposited in the China General Microorganism Culture Collection and Management Center on July 2, 2019, with the preservation number CGMCC No.18172. The present invention describes the antigenic variation of the isolated virus strain from the molecular level; after formaldehyde inactivation, the inactivated vaccine is prepared with 605 adjuvant, and the 21-day-old SPF chicken is immunized, and the immune effect is evaluated by serological methods and immune challenge methods. It is confirmed that the strain has a better protective effect and can be used as a candidate strain for avian influenza H9N2 subtype vaccine. The invention provides ideas for the prevention and control of bird flu, provides technical guidance for screening candidate strains of bird flu, and has important public health significance.

The invention provides polypeptide for preparing a cattle foot-and-mouth disease ASIAI type peptide vaccine. The polypeptide comprises an amino acid sequence shown as SEQIDNO.1 and the peptide vaccine comprising the polypeptide. The cattle foot-and-mouth disease ASIAI type combined peptide vaccine is good in immune potency and does not cause the problems of a fever, swelling and the like caused by a tradition vaccine. Thus, the polypeptide for preparing the cattle foot-and-mouth disease ASIAI type peptide vaccine can effectively solve the problems of antigen and variation and nonexistence of bio-security of an existing foot-and-mouth disease virus, can be easily synthesized massively and has a good application prospect. The invention further provides a preparing method and use of the polypeptide and the peptide vaccine.

The invention provides polypeptide used for preparing O type peptide vaccine of cattle foot-and-mouth disease. The polypeptide comprises an amino acid sequence presented by SEQ ID NO.1 and the peptide vaccine containing the polypeptide. The O type synthetic peptide vaccine of cattle foot-and-mouth disease provided by the invention has excellent immune efficacy, and cannot cause the problems of fever, swelling and the like existing in traditional vaccines, so that the vaccine can effectively respond to antigenic variation of current foot-and-mouth disease virus, prevents biosecurity problems, is easy to synthesize in a large scale, and has an excellent application prospect. The invention further provides preparation methods and pharmaceutical applications of the polypeptide and the peptide vaccine.

The invention relates to the field of animal virology, and provides separation identification and purification methods, biological characteristics and applications in biology of a recombinant fowl H9N2 avian influenza virus strain with preservation number being CCTCC NO:V200811; the differences between the virus and other separation strains are explained in term of molecular level; and the virus strain is proved to be capable of being used as candidate strain of avian influenza vaccines and as antigen of H9 subtype AIV hemoagglutination and hemoagglutination inhibition test (HA-HI). The strain has significance in knowing the molecular evolution and antigenic variation of fowl H9N2 avian influenza virus in China.

The invention provides antigen peptides for preparing a porcine circovirus synthetic peptide vaccine as well as an application. The antigen peptides are peptides shown in the sequence 2, the sequence3 or the sequence 4. The porcine circovirus synthetic peptide vaccine has excellent immune efficiency, and the existing problems of fever, inflammation and the like of traditional vaccines cannot be caused. As a result, the vaccine can effectively cope with present antigen variation of porcine circovirus and no biosecurity, is prone to synthesis on a large scale, and has bright application prospects. The invention also provides a preparation method of the peptides and the peptide vaccine as well as a pharmaceutical application thereof.

The invention discloses an antigen polypeptide for preparing a porcine circovirus synthetic peptide vaccine, a polypeptide composition and a vaccine. The antigen polypeptide is a polypeptide with sequence 1 or sequence 2. The vaccine comprises the polypeptide or the polypeptide composition. The porcine circovirus synthetic peptide vaccine provided by the invention has good immune potency, and does not induce fever, swelling and other problems like traditional vaccines. Therefore, the vaccine of the invention can effectively deal with the antigenic variation of porcine circovirus, has good biosafety, is easy for large-scale synthesis, and has good application prospects. The invention also provides a preparation method and pharmaceutical applications of the polypeptide and the polypeptide vaccine.

The invention provides an antigen polypeptide composition and vaccine for preparing a cow foot-and-mouth disease O-type and A-type divalent synthetic peptide vaccine. The antigen peptide composition comprises polypeptides as shown in sequence 1 and sequence 2. The vaccine in the invention comprises the polypeptide composition. The cow foot-and-mouth disease O-type and A-type divalent synthetic peptide vaccine provided by the invention has good immunological efficiency, and the antigen of the vaccine is chemically synthetic peptide and does not contain foot-and-mouth disease viral nucleic acid particles, and the safety is high. Therefore, the vaccine in the invention can effectively solve antigenic variation of current foot-and-mouth disease virus, the biological safety is low, and the vaccine is easy for large-scale synthesis and has a good application prospect. The invention also provides a preparation method and pharmacy application of polypeptide and peptide vaccines.

The invention relates to the field of animal virology, and provides separation identification and purification methods, biological characteristics and applications in biology of a recombinant fowl H9N2 avian influenza virus strain with preservation number being CCTCC NO:V200812; the differences between the virus and other separation strains are explained in term of molecular level; and the virus strain is proved to be capable of being used as candidate strain of avian influenza vaccines and as antigen of H9 subtype AIV hemoagglutination and hemoagglutination inhibition test (HA-HI). The strain has significance in knowing the molecular evolution and antigenic variation of fowl H9N2 avian influenza virus in China.

The invention discloses an antigen polypeptide for preparing a canine parvovirus synthetic peptide vaccine, a polypeptide composition and a vaccine. The antigen polypeptide is a polypeptide shown as asequence 1 or a sequence 2. The vaccine comprises the polypeptide or the polypeptide composition. The vaccine prepared from the polypeptide is capable of effectively coping with antigen variation ofthe canine parvovirus, is free of the problem of safety and easy to synthesize in large scale, and has good application prospects.

The invention provides a swine fever synthesized peptide vaccine and a preparation method thereof. The invention specifically relates to polypeptide used for synthesizing the swine fever synthesized peptide vaccine, a vaccine containing the polypeptide, and a preparation method thereof. The amino acid sequence of the polypeptide is represented by SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, or SEQ ID No.4. With the vaccine prepared from the polypeptide, antigen variations of swine fever viruses can be effectively coped with, and a bio-security problem is avoided. The polypeptide vaccine is suitable for large-scale synthesizing, and has a good application prospect.

The invention provides O-type aftosa synthetic peptide vaccine, and in particular relates to polypeptide or polypeptide polymer thereof used in the vaccine as well as the vaccine containing the polypeptide or the polypeptide polymer thereof and a preparation method thereof. The polypeptide has amino acid sequences shown in SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3. The O-type aftosa synthetic peptide vaccine carries out chemical synthesis of potential antigen site peptide segments by carrying out sequencing of domestic aftosa epidemic strains to study the variation of the main antigen sites ofaftosa and combining with computer assistant to carry out antigen site analytical prediction. Candidate polypeptide antigens are screened out by carrying out large numbers of animal experiments and aftosa virus antigen sites are optimized according to the screening result; and T cell epitope and B cell epitope are effectively combined to improve the immune effects of the polypeptide antigens. TheO-type aftosa synthetic peptide vaccine can effectively cope with the antigen variation of aftosa virus and has ideal biosafety and easy large-scale synthesis, thereby having a good application prospect.